EU approves Agios’ Pyrukynd as first oral treatment for adult thalassemia

Agios Pharmaceuticals (NASDAQ:AGIO) announced that the European Commission has granted marketing authorization for Pyrukynd (mitapivat) to treat anemia in adult patients with alpha- or beta-thalassemia.

The approval includes orphan medicinal product designation and covers both transfusion-dependent and non-transfusion-dependent patient populations.

With this regulatory milestone, the oral pyruvate kinase (PK) activator becomes the only approved medicinal treatment available across all European Union member states for this broad, adult thalassemia demographic.

Thalassemia is an inherited blood disorder characterized by impaired hemoglobin production, resulting in chronic hemolytic anemia, systemic complications, and a severe reduction in patient quality of life.

Current disease management strategies have historically been restricted to supportive care, including frequent red blood cell transfusions and iron chelation therapy.

The European Commission's decision is supported by data from two pivotal global Phase 3 clinical trials: ENERGIZE, which evaluated adults with non-transfusion-dependent thalassemia, and ENERGIZE-T, which focused on adults with transfusion-dependent forms of the disease.

Both trials met their primary efficacy endpoints, demonstrating statistically significant improvements in hemoglobin responses and a meaningful reduction in transfusion burdens, respectively.

Commercial rollout and distribution across the European Economic Area, the United Kingdom, and Switzerland will be executed by Agios' pan-European partner, Avanzanite Bioscience, under an exclusive commercialization agreement established last year.